TGL WHAAAAAAAT! Alerts, thoughts, discussion. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : TGL WHAAAAAAAT! Alerts, thoughts, discussion.

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Jim Bishop who wrote ()	2/4/2000 12:30:00 AM
From: etcobbe	of 150070

Dwight here is my DD for BBII, also check raging bull board. Some good info from posters there. Not only HIV - Great stories everywhere. Check out the other news releases biz.yahoo.com biz.yahoo.com Plus todays news: biz.yahoo.com They have good revenues. Most bitechs don't. In last nine months- $21 million in revenues and a loss of only $700 thousand. This company is a jewel. 27% of float was bought by institutions last quarter. Float is 2.6 million, outstanding shares are 4.77. This is nice for a good rise. Boston Biomedica, Inc. offers products and services primarily to the in vitro diagnostic infectious disease industry. There are two broad product classes: Diagnostic Products and Laboratory Instruments. Diagnostic Products consist of three groups: Quality Control Panels, Accurun Run Controls, and Diagnostic Components, all of which are used in connection with infectious disease testing. The Company also offers a variety of services, which includes Specialty Clinical Laboratory Testing, Contract Research, Clinical Trials, Laboratory Instrumentation Services, and Drug Screening. Financial Summary Boston Biomedica, Inc. is a provider of proprietary quality control products for use with in vitro diagnostic test kits for the detection, analysis and monitoring of infectious diseases. For the nine months ended 9/30/99, total revenues increased 14% to $21.5 million. Net loss decreased 82% to $719 thousand. Revenues reflect growth in Accurun(R), diagnostic component and lab instrument sales. Lower loss reflects the absence of charge for in-process research and development.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next